Effects of dapagliflozin and dulaglutide on blood pressure and coronary flow in liver steatosis patients with type 2 diabetes - PubMed
2 hours ago
- #Liver Steatosis
- #Type 2 Diabetes
- #Cardiovascular Function
- Dapagliflozin (SGLT-2i) and dulaglutide (GLP-1RA) improve cardiovascular function and reduce hepatic steatosis in patients with type 2 diabetes (T2DM) and metabolic-dysfunction associated steatotic liver disease (MASLD) after 12 months.
- Both treatments significantly reduced central systolic blood pressure, arterial stiffness (pulse wave velocity), and liver steatosis (controlled attenuation parameter), while increasing coronary flow reserve and left ventricular global longitudinal strain.
- Dulaglutide showed greater improvements in myocardial function (global longitudinal strain) and glycocalyx thickness compared to dapagliflozin and DPP-4 inhibitors.
- Improvements in blood pressure and coronary flow were associated with better glycocalyx health, reduced arterial stiffness, and enhanced cardiac function.
- Reductions in liver steatosis were linked to improvements in vascular and cardiac parameters.